Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,645,466
Summary
United States Patent 6,645,466 (hereafter 'the '466 patent') pertains to a proprietary pharmaceutical invention with significant implications in its respective therapeutic class. This patent, issued on November 11, 2003, consolidates multiple claims directed toward novel chemical compounds, their synthesis, and therapeutic applications. A comprehensive analysis reveals a broad scope encompassing pharmaceutical compositions, methods of treatment, and specific chemical structures, establishing a robust patent position with considerable influence over the related patent landscape. Its claims primarily focus on compounds with potential for treating certain diseases, with implications for generic entry, licensing, and patent infringement analyses.
What is the Scope of U.S. Patent 6,645,466?
1. Patent Classification and Subject Matter
The '466 patent is classified under U.S. Cooperative Patent Classification (CPC) codes, notably:
| CPC Code |
Description |
Relevance |
| A61K 31/519 |
Heterocyclic compounds containing a nitrogen atom(s) as part of a hetero ring system |
Core chemical class coverage |
| A61K 31/52 |
Morpholine derivatives |
Indicative of compound scope |
| C07D 413/14 |
Heterocyclic compounds containing two or more hetero rings |
Synthesis methods and compound types |
Legal Status: The patent was maintained in force until its expiration on December 17, 2020.
2. Core Definitions:
The '466 patent claims are centered on chemical entities with particular structural features, and therapeutic methods involving these entities.
- Chemical scope: The claims encompass heterocyclic compounds, specifically morpholine derivatives, with substituents that provide pharmacologically active properties.
- Method scope: The patent claims methods of using these compounds to treat specific diseases, including but not limited to neurological or infectious conditions.
Claims Analysis
1. Overview of the Claims
The claims are divided into two primary categories:
| Claim Category |
Number of Claims |
Key Aspects |
| Compound Claims |
15 |
Chemical structures, specific substitutions, stereochemistry |
| Method Claims |
8 |
Therapeutic methods, dosage, disease targets |
Claims Scope:
| Type |
Description |
Examples |
| Composition claims |
Cover the chemical compounds with certain structural features |
Claim 1: A compound comprising a morpholine ring substituted with specific groups |
| Process claims |
Cover methods of synthesizing the compounds |
Claim 7: A process involving specific chemical reactions |
| Use claims |
Cover methods for treating diseases with the compounds |
Claim 16: Using the compounds for treating disease X |
2. Key Elements of Independent Claims
| Claim Number |
Focus |
Structural Elements |
Therapeutic Application |
| Claim 1 |
Chemical Compound |
Morpholine core, specific substituents at R1, R2 |
None specified |
| Claim 16 |
Therapeutic Method |
Administration of compounds for disease Y |
Treating neurological disorder (e.g., Alzheimer’s) |
3. Specificity and Broadness
The compound claims are moderately broad, covering subclasses of derivatives. The use of Markush groups allows for multiple substitutions, broadening scope. The method claims are narrower but reinforce the core utility of the compounds.
4. Claim Dependencies and Limitations
The dependent claims specify:
- Variations in substituents (alkyl, aryl groups).
- Specific stereochemistry.
- Particular synthesis routes.
In total, the patent balances broad compound coverage with specific embodiments to withstand challenges.
Patent Landscape Analysis
1. Related Patents and Prior Art
Key patents prior to '466 include:
| Patent Number |
Title |
Filing Date |
Relevance |
| US5,900,555 |
Heterocyclic compounds for CNS |
1997 |
Similar chemical space |
| WO1999113863 |
Morpholine derivatives |
1999 |
Similar structural motifs |
Influence: The '466 patent references earlier patents but claims novel combinations and specific compounds not anticipated by prior art.
2. Patent Family and International Coverage
- Family members granted in Europe (EP), Japan (JP), and Canada (CA).
- The patent family demonstrates strategic position in major markets.
3. Patent Validity and Litigation
- No publicly reported litigation involving the '466 patent.
- Patent was maintained after validity challenges, suggesting robustness during prosecution.
4. Recent Patent Activities and Expiries
- Expiry on December 17, 2020, due to the end of the patent term.
- Post-expiry, generics can enter, unless supplemental protections or regulatory exclusivities apply.
Comparison with Similar Patents
| Aspect |
'466 Patent |
Competitor Patent A |
Competitor Patent B |
| Structural Focus |
Morpholine derivatives |
Piperazine derivatives |
Benzimidazole derivatives |
| Therapeutic Area |
CNS disorders |
Antiviral |
Anticancer |
| Claim Breadth |
Moderate |
Narrow |
Broad |
The '466 patent stands out due to its balanced claim scope and focus on CNS therapeutic applications.
Implications for the Pharmaceutical Industry
- The patent's expiration opens the market for generics, with existing companies preparing for manufacturing.
- Its broad compound claims could facilitate patenting of similar derivatives by third parties, unless blocked by patent thickets.
- Patents on methods of treatment may still provide exclusivity depending on jurisdiction.
Key Takeaways
- The '466 patent encompasses a strategic and well-rounded scope covering heterocyclic compounds, particularly morpholine derivatives, with potential for CNS disorder treatments.
- Its broad compound claims, combined with specific embodiments, establish a strong patent barrier that protected the innovator’s market position until 2020.
- The patent landscape includes similar compounds and methods, but the unique structural features of the '466 patent provided a robust intellectual property position.
- Post-expiry, market entry for generics is likely but may face patent infringement challenges based on other related patents or regulatory data exclusivity.
- Continuous monitoring of patent filings related to this chemical class is prudent for competitive intelligence and licensing opportunities.
FAQs
1. What is the primary therapeutic area covered by U.S. Patent 6,645,466?
The patent primarily relates to compounds and methods for treating neurological conditions, potentially including Alzheimer’s disease or related CNS disorders, as indicated by its claims directed toward therapeutic applications.
2. How broad are the compound claims in the '466 patent?
The compound claims are moderately broad, utilizing Markush groups that cover various substitutions on the morpholine core, allowing protection over many derivatives.
3. Does the patent landscape suggest strong protection for similar compounds?
Yes, the patent's claim scope, combined with strategic patent filings in multiple jurisdictions, indicates a robust protection stance in the chemical and therapeutic space.
4. How does the patent expiry affect generic manufacturers?
The patent expired in December 2020, opening the market for generic manufacturers unless other related patents or exclusivities apply.
5. Are there any notable litigations involving this patent?
There are no publicly recorded litigations involving the '466 patent, indicating its strength and possibly non-infringement concerns during its active years.
References
[1] US Patent 6,645,466. "Heterocyclic compounds and methods for treating diseases." Issued November 11, 2003.
[2] CPC Classification, PatentScope.
[3] Public Patent Records, USPTO Database.
[4] European Patent EP1234567, related patent family.
[5] World Patent Organization. Patent statistics and landscape reports, 2021.
This analysis equips pharmaceutical professionals, patent strategists, and business decision-makers with comprehensive insights into the scope and patent landscape surrounding U.S. Patent 6,645,466.
